Ottawa, Canada & Pittsburgh, USA, July 12, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery company targeting previously undruggable G Protein-Coupled Receptors (GPCRs), and Peptilogics, a biotech company engineering peptide therapeutics by combining computation and biology to improve the treatment landscape for patients with life-threatening diseases, announced today that they have entered a research and development collaboration to leverage AI for drug discovery against an undrugged GPCR target.
The collaboration will combine the capabilities of Peptilogics’ AI platform (NautilusTM) with Orion Biotechnology’s proprietary drug discovery platform. The companies will leverage expertise in peptide design and engineering to drive drug discovery against an undrugged peptidergic GPCR linked to highly prevalent, life-threatening diseases.
Peptilogics’ Nautilus™ platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom design therapeutics. Additionally, Peptilogics’ supercomputer accelerates model development and prediction and evaluation of peptide sequences, to produce higher-quality hits with greater chance of success. Synergistically, Orion Biotechnology’s platform explores receptor-ligand shape space using proprietary multiplex synthesis technology to generate precision-engineered peptides with enhanced potency and tailored signaling activity. Orion’s platform generates data matrices for AI-assisted lead optimization, offering one of the fastest drug discovery and development solutions to target peptidergic GPCRs.
On the announcement of this collaboration, Dr. Oliver Hartley, VP Drug Discovery at Orion Biotechnology commented “We are pleased to be partnering with Peptilogics to push the boundaries of receptor pharmacology and AI computing to accelerate innovation for improved patient outcomes. An AI-driven paradigm shift is happening in drug discovery, and Orion is pleased to be at the forefront of applying AI to the highly valuable space around GPCRs. The ideal fit between Orion’s platform and unique knowledge of receptor-ligand interactions with Peptilogics’ machine learning models will position us to make AI-driven GPCR drug discovery a reality.”
“Using Peptilogics’ Nautilus™ platform, we combine proprietary deep generative models, predictive models, and biophysical simulation to design multiparameter-optimized peptides that have the potential to address historically challenging and novel drug targets. Our AI algorithms enable efficient navigation of the vast peptide design space, allowing us to uncover molecules that may not be discovered through traditional screening,” said Nicholas Nystrom, Ph.D., Chief Technology Officer of Peptilogics. “We are excited to partner with Orion Biotechnology for their deep GPCR expertise. By combining the strengths of Peptilogics’ Nautilus™ AI-driven peptide design platform and Orion’s GPCR platform, we aim to reduce the risk, time, and cost for drug design.”
About Orion Biotechnology
Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs). Orion’s world-renowned experts in GPCR pharmacology and peptide/protein engineering leverage Orion’s proprietary drug discovery platform to rapidly and efficiently advance a diversified portfolio of precision engineered GPCR-targeted therapeutic candidates for the treatment of cancer and other serious diseases. To learn more, follow the company on LinkedIn or visit https://orionbiotechnology.com/.
About Peptilogics
Peptilogics engineers peptide therapeutic candidates to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Peter Thiel, Presight Capital, Founders Fund, CARB-X, and Cystic Fibrosis Foundation. For more information about Peptilogics, visit www.peptilogics.com or follow the company on Twitter and LinkedIn.
Attachment
